- Brexit in practice—Member States compete to host the European Medicines Agency
- What is the EMA, what work does it do, and why is it moving?
- Why does it matter where the agency is relocated to, and why is competition to host it so fierce?
- What are the criteria for evaluation of the bids?
- Which countries have submitted bids?
- What are the bidding Member States proposing?
- What is the procedure for the decision-making process?
- When will we know the outcome?
- When will the relocation happen?
- What will be the impact of the work carried out by the EMA, in particular with regards to the marketing authorisation procedure application?
- What is the possible impact of the EMA’s relocation on the MHRA’s role and its work?
IP analysis: Julia Gillert and Els Janssens, senior associates at Baker McKenzie, explain what is happening to the European Medicines Agency (EMA) in the context of Brexit and why the competition to host the EU agency when it leaves its London base is proving to be so fierce.
Sign in or take a trial to read the full analysis.
To continue reading this news article, as well as thousands of others like it, sign in to LexisPSL or register for a free trial